The Dementia Consortium, a public-private partnership based in the UK, is now dedicating close to $500 thousand dollars to a project for the discovery and development of drugs for ALS and frontotemporal lobar degeneration (FTLD). The consortium is a collaboration between Alzheimer’s Research UK, Medical Research Council (MRC) Technology, and the private companies Eisai and Eli-Lilly. The project, which will be carried out in part by researchers at the Italian non-profit organization International Centre for Genetic Engineering and Biotechnology (ICGEB), is aiming to identify drugs that clear the aberrant, cytosolic aggregations of TDP-43, a pathologic feature of both ALS and FTD. Several promising compounds have been identified that increase clearance of TDP-43 aggregates, and these compounds are undergoing further validation at the MRC to establish the mechanism of action and effect in animal models.
Click here to read more.